logo-loader
SCYNEXIS, Inc.

SCYNEXIS reveals positive interim data from its Phase 3 FURI study

SCYNEXIS, Inc. (NASDAQ:SCYX) President & CEO Dr. Marco Taglietti sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biotechnology company's lead product candidate is ibrexafungerp (formerly known as SCY-078), an IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections

Quick facts: SCYNEXIS, Inc.

Price: $1.15

Market: NASDAQ
Market Cap: $64.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources releases more positive drill results...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to discuss their latest assay results from the drill program on the Dixie Project in Red Lake.  Taylor discusser the results from the Hinge and Dixie Limb zones and also gave...

18 hours, 45 minutes ago

2 min read